If you take ISLA-101 out of the equation all together. Which we...

If you take ISLA-101 out of the equation all together. Which we shouldn't given it can provide immense value ($1+) Think about potential numbers for Galidesivir alone.

It's got broad antiviral activity across multiple viruses, which is critical for its potential stockpiling and use across various viral threats (e.g., Marburg, Ebola, Zika, etc.).

Let's take a look at Marburg which has a fatality rate above 90%. There are no vaccines or therapies approved for it (unlike zika and ebola). Galidesivir has shown 100% survival rates in animal studies against Marburg. This is as long as it is administered within 48 hours post infection. Given the virus's lethality, any effective treatment would likely be fast tracked by governments for stockpiling and emergency use. Marburg virus is classified as a Category A bioterrorism agent, meaning it poses a significant threat to public health, has a high mortality rate, and requires immediate action in the event of an outbreak.

It has a viral clearance of 14 days so the trial can be done very quickly but they will need a good animal model/s. They could race to FDA approval within 18 months if not earlier.

PRV with a 25% discount is $112.5million AUD / 270 million shares on issue would bring this to around 45c per share based on Galidesivir pre revenue alone. Just Galidesivir not ISLA-101.

Small pox is also Category A bioterrorism agent (eventhough the WHO considers it irradicated and there are no natural cases). Last year the U.S government ordered $138 million USD of tpoxx for stockpiling
https://globalbiodefense.com/2023/07/27/smallpox-countermeasures-u-s-awards-138m-to-siga-technologies-for-tpoxx/

We could see numbers similair to this for Galidesivir. Let's say it's $100 million USD that's around 150million AUD. This would bring the Galidesivir component up to 90c+ with just U.S military stockpiling.. not NATO or general use. Then add ISLA-101 and the potential is very high here.